Literature DB >> 16344072

Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C.

Tarik Asselah1, Ivan Bièche, Ingrid Laurendeau, Valérie Paradis, Dominique Vidaud, Claude Degott, Michelle Martinot, Pierre Bedossa, Dominique Valla, Michel Vidaud, Patrick Marcellin.   

Abstract

BACKGROUND & AIMS: The molecular mechanisms of hepatocellular carcinoma have been studied, but little is known of the changes in liver gene expression during the different stages of chronic hepatitis C virus (HCV) infection, in particular the transition from mild to moderate fibrosis.
METHODS: We used real-time quantitative RT PCR to study the messenger RNA expression of 240 selected genes in 2 pools of liver specimens according to the stages of fibrosis (Metavir score; mild fibrosis = F1 and septal fibrosis = F2). Genes whose expression differed between pools (F2 vs F1) by at least 2-fold were selected. In addition, the expression level of these selected genes then was assessed in each of the 62 individual samples (F4, n = 6; F3, n = 17; F2, n = 21; vs F1, n = 18).
RESULTS: The 22 genes that were up-regulated in the 21 F2 samples relative to the 18 F1 samples mainly encoded genes involved in cytoskeleton (KRT 19 and SCG 10), growth factors/cytokines (CXCL6, interleukin 8 [IL8], IL1A, IL2, and CXCL10), or growth factor receptors (CCR2, CXCR3, and CXCR4), or were involved in extracellular matrix production (COL1A1, CHI3L, and SPP1), in extracellular matrix remodeling (TIMP1, MMP7, and MMP9), and in cell junction (ITGA2 and CLDN 4). When hierarchically clustering the F2 and F1 samples according to the expression of the 11 most discriminatory genes (KRT 19, COL1A1, STMN2, CXCL6, CCR2, TIMP1, IL8, IL1A, ITGA2, CLDN 4, and IL2), the patient population was categorized into 2 subgroups: F1 and F2. Specifically, 15 of 18 F1 (83%) and 19 of 21 F2 (90%) were classified correctly (P < 10(-5)). We also studied the messenger RNA expression of these 240 selected genes in normal liver in comparison with F1. Genes dysregulated in the transition from normal liver to F1 mainly were interferon-inducible genes, and therefore were very different from those dysregulated in the transition from F1 to F2.
CONCLUSIONS: Genes involved in extracellular matrix turnover and immune response are implicated in the transition from mild to moderate fibrosis. Eleven of the genes could form the basis for the gene expression signature of mild versus moderate fibrosis in patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344072     DOI: 10.1053/j.gastro.2005.09.010

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  57 in total

1.  Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.

Authors:  S Johansson; W Talloen; M Tuefferd; J M Darling; A Scholliers; G Fanning; M W Fried; J Aerssens
Journal:  Aliment Pharmacol Ther       Date:  2015-08-28       Impact factor: 8.171

2.  Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients.

Authors:  Frédérique Caillot; Martine Hiron; Odile Goria; Marie Gueudin; Arnaud Francois; Michel Scotte; Maryvonne Daveau; Jean-Philippe Salier
Journal:  Am J Pathol       Date:  2009-05-28       Impact factor: 4.307

3.  Robustly detecting differential expression in RNA sequencing data using observation weights.

Authors:  Xiaobei Zhou; Helen Lindsay; Mark D Robinson
Journal:  Nucleic Acids Res       Date:  2014-04-20       Impact factor: 16.971

4.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

5.  Dysregulation of upstream and downstream transforming growth factor-β transcripts in livers of children with biliary atresia and fibrogenic gene signatures.

Authors:  Tatiana Iordanskaia; Monica J Hubal; Emily Koeck; Christopher Rossi; Kathleen Schwarz; Evan P Nadler
Journal:  J Pediatr Surg       Date:  2013-10       Impact factor: 2.545

6.  Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro.

Authors:  Karla J Helbig; Andrew Ruszkiewicz; Robert E Lanford; Mark D Berzsenyi; Hugh A Harley; Shaun R McColl; Michael R Beard
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

7.  Modulations of cell cycle checkpoints during HCV associated disease.

Authors:  Saira Sarfraz; Saeed Hamid; Syed Ali; Wasim Jafri; Anwar A Siddiqui
Journal:  BMC Infect Dis       Date:  2009-08-10       Impact factor: 3.090

8.  Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.

Authors:  Jordi Colmenero; Ramón Bataller; Pau Sancho-Bru; Marlene Domínguez; Montserrat Moreno; Xavier Forns; Miquel Bruguera; Vicente Arroyo; David A Brenner; Pere Ginès
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-23       Impact factor: 4.052

9.  Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice.

Authors:  Claudia Mitchell; Dominique Couton; Jean-Pierre Couty; Marie Anson; Anne-Marie Crain; Vinciane Bizet; Laurent Rénia; Stanislas Pol; Vincent Mallet; Hélène Gilgenkrantz
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

10.  Significant gene expression differences in histologically "Normal" liver biopsies: Implications for control tissue.

Authors:  Tarik Asselah; Ivan Bièche; Ingrid Laurendeau; Michelle Martinot-Peignoux; Valerie Paradis; Dominique Vidaud; Dominique-Charles Valla; Pierre Bedossa; Patrick Marcellin; Michel Vidaud
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.